Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed
the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic …

The physiology of B cells is intimately connected with the function of their B‐cell receptor
(BCR). B‐cell lymphomas frequently (dys) regulate BCR signalling and thus take advantage …

B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia
(CLL). Bruton tyrosine kinase (BTK) is essential to BCR signaling and in knockout mouse …

B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic
leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR …

The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell
malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of …

The B cell receptor (BCR) and its precursor (pre-BCR) control B cell homeostasis,
differentiation and function. Moreover, aberrant pre-BCR and BCR signalling have a central …

In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of
the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck …

During the past 5 years, a number of highly active novel agents, including kinase inhibitors
targeting BTK or PI3Kδ, an antagonist of the antiapoptotic protein BCL-2, and new anti …

Abstract Purpose of Review While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has
revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations …

Tyrosine kinases belong to a family of enzymes that mediate the movement of the phosphate
group to tyrosine residues of target protein, thus transmitting signals from the cell surface to …